SNAIL tagged posts

CDK4/6 inhibition inhibits cancer metastasis.

Breast cancer metastasis, the process by which cancer spreads, may be prevented through the new use of a class of drugs already approved by the FDA. Mayo Clinic researchers have identified that a key drug target, CDK4/6, regulates a cancer metastasis protein, SNAIL, and drugs that inhibit CDK 4/6 could prevent the spread of triple-negative breast cancer. CDK4/6 inhibitors are approved for treating estrogen positive breast cancer, but not triple-negative breast cancer.

For this study, Dr. Lou and his colleagues focused on triple-negative breast cancer, which is difficult to treat, because it does not exhibit receptors for estrogen, progesterone or the HER-2/neu gene, which are targets for many current breast cancer treatments...